Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours

Bone Marrow Transplantation

Volumn 18, Issue 6, 1996, Pages 1043-1047

  Shaw, P J ^a   Pinkerton, C R ^b   Yaniv, I ^c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Carboplatin; Childhood cancer; Melphalan; Neuroblastoma

Indexed keywords

CARBOPLATIN; MELPHALAN;

ADVANCED CANCER; ARTICLE; AUTOTRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FATALITY; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NEUROBLASTOMA; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GLOMERULAR FILTRATION RATE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFECTION; KIDNEY DISEASES; MALE; MELPHALAN; NEOPLASMS; NEUROBLASTOMA; TREATMENT OUTCOME;

EID: 0030471439     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ladenstein R, Hartmann O, Pinkerton CR. The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood. Ann Oncol 1993; 4 (Suppl.I): S45-S58.
2. Shafford EA, David WR, Pritchard J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 1984; 2: 742-747.
3. Corbett R, Pinkerton R, Pritchard J et al. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992; 28A: 1324-1328.
4. Gordon SJ, Pearson ADJ, Reid MM et al. Toxicity of singleday high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992; 28A: 1319-1323.
5. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 17: 1748-1756.
6. Yaniv I, Goshen Y, Newman S et al. Peripheral blood stem cells (PBSC) as a source for hemopoietic recovery following autologous bone marrow transplantation (ABMT) in childhood malignancy. Med Pediatr Oncol 1993; 21: 563 (Abstr. 33).
7. Brodeur GM, Seeger RC, Barrett A et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874-1881.
8. Geyer JR, Pendergrass TW, Milstein JM et al. Eight drugs in one day chemotherapy in children with brain tumours: a critical toxicity appraisal. J Clin Oncol 1988; 6: 996-1000.
9. Morgan RR, Gaynon PS, Herzog P et al. A pilot study of '6 in 1' chemotherapy (CT) for poor risk neuroblastoma (NBL). Proc ASCO 1988; 7: 266.
10. Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876-3885.
11. Pritchard J, Germond S, Jones D et al. Is high dose melphalan (HDM) of value in treatment of advanced neuroblastoma (AN)? Preliminary results of a randomised trial by the European Neuroblastoma Study Group. Proc ASCO 1986; 5: 205 (Abstr. 805).
12. Castleberry RP, Cantor AB, Green AA et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide. and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1994; 12: 1616-1620.
13. Ettinger LJ, Gaynon PS, Krailo MD et al. A phase II study of carboplatin in children with recurrent or progressive solid tumours. A report from the Children's Cancer Group. Cancer 1994; 73: 1297-1301.
14. Lewis IJ, Stevens MC, Pearson AD et al. Carboplatin activity in cisplatin treated neuroblastoma. Prog Clin Biol Res 1991; 366: 553-559.
15. Brandt LJ, Broadbent V. Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary? Med Pediatr Oncol 1993; 21: 31-35.
16. 2 in children. Med Pediatr Oncol 1990; 18: 459-465.
17. Gore ME, Calvert AH, Smith IE. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol 1987; 23: 1391-1397.
18. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-661.
19. Santana VM, Schell MJ, Williams R et al. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumours. Bone Marrow Transplant 1992; 10: 457-462.
20. Hardy JR, Tan S, Fryatt I et al. How nephrotoxic is carboplatin? Br J Cancer 1990; 61: 644.
21. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin and ormaplatin. Gynecol Oncol 1993; 50: 147-158.
22. Newell DR, Pearson ADJ, Balmanno K et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993; 11: 2314-2323.
23. Tranchard B, Ardiet C, Bouffet E. Efft du carboplatine sur la pharmacocinétique du melphalan administré par voie intraveneuse. Bull Cancer 1994; 81: 43-46.
24. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482-1488.
25. Pearson AD, Pinkerton CR, Lewis IJ, ENSG 5: A randomised study of dose intensity in stage 4 neuroblastoma over the age of one. Adv Neuroblastoma Res (in press).
26. Shaw PJ, Goletta-Dy A, Dalla-Pozza L et al. High-dose cyclophosphamide combined with chemoradiotherapy prior to BMT for advanced neuroblastoma. Med Pediatr Oncol 1991; 19: 404-405 (Abstr. 248).
27. Pinkerton CR, Groot-Loonen J, Barrett A et al. Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas. Br J Cancer 1991; 64: 381-385.
28. Bearman SI, Applebaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.